Business mix
- Women's health: non-invasive prenatal screening and carrier screening are important revenue bases.
- Oncology: ctDNA and molecular residual disease tests support cancer monitoring, treatment response, and recurrence-risk assessment.
- Organ health: transplant monitoring and organ-health testing expand long-term clinical use cases.
Current key questions
- Can test-volume growth, average selling price, and reimbursement keep supporting revenue expansion?
- Can oncology and organ-health products use clinical data to broaden indications and physician adoption?
- When can the company produce durable cash flow and margin improvement despite high R&D, sales, and lab-processing costs?
